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Abstract
In addition to its neurotrophic role, brain-derived neurotrophic factor (BDNF) is involved in a wide array of
functions, including anxiety and pain. The central amygdaloid nucleus (CeA) contains a high concentration of
BDNF in terminals, originating from the pontine parabrachial nucleus. Since the spino-parabrachio-amygdaloid
neural pathway is known to convey nociceptive information, we hypothesized a possible involvement
of BDNF in supraspinal pain-related processes. To test this hypothesis, we generated localized deletion of BDNF
in the parabrachial nucleus using local bilateral injections of adeno-associated viruses in adult ﬂoxed-BDNF
mice. Basal thresholds of thermal and mechanical nociceptive responses were not altered by BDNF loss and no
behavioural deﬁcit was noticed in anxiety and motor tests. However, BDNF-deleted animals displayed a major
decrease in the analgesic eﬀect of morphine. In addition, intra-CeA injections of the BDNF scavenger TrkB-Fc in
control mice also decreased morphine-induced analgesia. Finally, the number of c-Fos immunoreactive nuclei
after acute morphine injection was decreased by 45% in the extended amygdala of BDNF-deleted animals. The
absence of BDNF in the parabrachial nucleus thus altered the parabrachio-amygdaloid pathway. Overall,
our study provides evidence that BDNF produced in the parabrachial nucleus modulates the functions of the
parabrachio-amygdaloid pathway in opiate analgesia.
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Introduction
Many aspects of the emotional, endocrine and auto-
nomic components of pain are mediated by the spino-
parabrachio-amygdaloid pathway, which sends
nociceptive information to the central extended amyg-
dala (EAc) via the parabrachial nucleus (PB) (Bernard et
al., 1996). The EAc is a continuum of basal forebrain
structures, stretching from the central nucleus of the
amygdala (CeA) caudally to the lateral bed nucleus of the
stria terminalis (BSTL) rostrally (Alheid et al., 1995;
Cassell et al., 1999). In the pain context, the EAc on the
one hand elaborates the aﬀective response to pain and on
the other exacerbates, facilitates or inhibits reactivity
to pain, by controlling aﬀective states (Neugebauer et al.,
2009). As such, the EAc and the neural projection trans-
ferring nociceptive signals to its components play an
important role in both endogenous and exogenous anal-
gesia, among which opioid-related analgesia.
The CeA is necessary for the expression of the mor-
phine analgesic properties as evidenced by lesion studies
in rodents and primates (Manning and Mayer, 1995;
Manning et al., 2001) and morphine suppresses electro-
physiological responses to nociceptive stimulus in CeA-
projecting PB neurons and in CeA neurons (Huang et al.,
1993a, b). The EAc is enriched with a wide range of
neuropeptides, most of which are released from ter-
minals originating from the PB (Yamano et al., 1988). One
of them, calcitonin gene-related peptide (CGRP), exerts
naloxone-dependent analgesic properties when injected
directly in the CeA (Xu et al., 2003). In our study, we are
speciﬁcally interested in brain-derived neurotrophic fac-
tor (BDNF), a neuropeptide present in axonal terminals
in the EAc originating from the PB (Conner et al., 1997).
In the EAc, BDNF positive terminals form pericellular
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baskets, similar to those described for CGRP (Yamano
et al., 1988 ; Conner et al., 1997 ; Agassandian et al., 2006),
and co-localization of CGRP and BDNF in the same
terminals within CeA has been described in rats and mice
(Salio et al., 2007). The BDNF role in neural plasticity is
clearly established in drug addiction (Graham et al., 2007;
Ghitza et al., 2010) and nociception (Pezet et al., 2002;
Merighi et al., 2008). A recent study demonstrated the
role of mesolimbic BDNF in the rewarding properties of
morphine (Koo et al., 2012). Regarding pain studies,
while most of the literature on BDNF and pain focuses on
the spinal cord, the supraspinal role of BDNF remains
unclear (Merighi et al., 2008). Considering the well-
described role of the parabrachio-amygdaloid pathway
in nociception, we formulated the hypothesis that BDNF
could modulate pain mechanisms in this pathway.
In this study, we investigated the role of PB BDNF in
morphine-induced analgesia using viral-mediated gene
deletion in ﬂoxed-BDNF mice (Adachi et al., 2008). We
ﬁrst deﬁned the parabrachio-amygdaloid pathway in
mice using a tract-tracing approach. Following anxiety
and motor skills assessment, we studied baseline pain
threshold and morphine-induced analgesia. Morphine-
induced analgesia was also tested after CeA injection
of the BDNF scavenger TrkB-Fc. We then examined the
impact of PB BDNF deletion on morphine-induced c-Fos
expression in the EAc and in the basolateral nucleus of
the amygdala (BLA). Our results reveal a critical role of
BDNF in the parabrachio-amygdaloid pathway in mor-
phine-induced analgesia.
Method
Animals
Experiments were performed using male transgenic mice
homozygous for a ﬂoxed allele (exon 5) encoding the
BDNF gene, with a C57BL/6J background (Rios et al.,
2001). Mice were housed four to ﬁve per cage in a colony
maintained at a constant temperature (23 xC) with a 12 h
light/dark cycle (lights on 07:00 hours) and ad libitum
food and water. The facilities are legally registered for
animal experimentation (Animal House Agreement B67-
482-1/C67-482-1) and scientists in charge of the experi-
ments possess the certiﬁcate authorizing experimentation
on living animals, delivered by the governmental veter-
inary oﬃce.
Surgeries
Mice were anaesthetized using either a 2.5% Avertin
solution or Ketamine–Xylazine (90–10 mg/kg respect-
ively). Surgeries were done according to a standard pro-
tocol, using glass micropipettes for tracer injections
(Sarhan et al., 2005) and Hamilton syringes for viral injec-
tions (Hommel et al., 2003). The following coordinates
from Bregma were used for the PB to target the external
lateral portion : 14x anteroposterior (AP) angle,x4.1 mm
AP, 1.4 mm mediolateral (ML), x4 mm dorsoventral
(DV). CeA targeting was x1.4 mm AP, 2.9 mm ML and
x3.9 to x4.1 mm DV from dura (Franklin and Paxinos,
2008). For intra-CeA injections of TrkB-Fc, stainless
26-gauge single guide cannulas were bilaterally im-
planted 500 mm above the CeA. They were aﬃxed to the
skull with dental cement. A 33-gauge dummy cannula
was inserted in each guide to avoid clogging and mice
were allowed to recover 7–8 d before testing.
Tract tracing
Tracers were iontophoretically injected. The anterograde
tracer biotin dextran amine (BDA; MW 10000; Molecular
Probes, USA; 2% in K-acetate 0.5 M) was injected in the PB
using a glass micropipette broken at 10 mm tip diameter
with a Midgard constant current source (+1 mA, 7 s on/
oﬀ, 15 min). The retrograde tracer hydroxystilbamidine
methanesulfonate (Fluoro-Gold1, FG, Fluorochrome,
USA; 2% in NaCl 0.5 M) was injected in the CeA with a
glass micropipette broken at 50 mm tip diameter (+3 mA,
7 s on/oﬀ, 10 min). Six to eight days after injection,
anaesthetized animals were ﬁxed by paraformaldehyde
perfusion, brainswere removed, sectioned on a vibratome
(Leica, Germany; 40 mm, frontal plane) and treated
for BDA histochemical revelation (Sarhan et al., 2005)
or analysed under the ﬂuorescence microscope (FG
injection).
Adeno-associated virus (AAV)-mediated deletion
of BDNF
Local expression of either enhanced green ﬂuorescent
protein (eGFP) alone or eGFP fused to the Cre re-
combinase was achieved using viral-mediated gene de-
livery (Berton et al., 2006). The DNA constructs were
cloned into an AAV-2 vector in which the genes of
interest were under the control of the ubiquitous cyto-
megalovirus promoter. Viral production was accom-
plished using a triple-transfection, helper-free method
and puriﬁed as described earlier (Hommel et al., 2003). A
total of 0.5 ml was bilaterally injected into the PB over
5 min (0.05 ml/30 s) and the needle was removed after
10 min. The age of mice at the time of deletion ranged
from 9 to 14 wk. Behavioural tests were conducted at
least 3 wk (usually 4–5 wk) following AAV injections.
BDNF expression assessment
In situ hybridization was done using a 1085 bp probe
based on the rat BDNF gene (accession number
NM_012513). The probe was labelled with [35S]UTP,
puriﬁed and used at 350 pM. Cryostat (Microm, France)
frontal sections (20 mm) were ﬁxed, acetylated, dehy-
drated and de-fatted prior to hybridization with the
probe in hybridization buﬀer at 54 xC overnight. Sections
were then washed, ﬁxed, treated with RNase and dehy-
drated, left to dry, then exposed to BioMax MR ﬁlms
for 6 d.
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Behavioral scoring
Assessors were blind to group assignment. Anxiety levels
were assessed with the dark–light, open-ﬁeld and elev-
ated plus-maze tests. Tests were performed during the
light phase, under controlled light conditions (90 lux),
videotaped and analysed using an automated video-
tracking system (Ethovision, USA). These tests were
conducted using the same animals with a 1 wk space
between tests.
Dark–light
The dark–light test was performed in place-preference
boxes (Med Associates, USA). One compartment was
dark while the other larger one was lit. Animals were
placed in the dark compartment for 2 min and the door
between the two compartments was opened allowing the
animal to freely move from one to the other for 10 min.
Photoelectric beams at the door detected when the animal
explored or entered the light compartment. Total time
spent in lit compartment was measured.
Open-ﬁeld
The open-ﬁeld test was conducted over 10 min. Animals
were placed in the centre of the apparatus (49 cmr49 cm
boxes). The average distance relative to the borders of the
box and the total distance were measured.
Elevated plus-maze
Micewere placed in the centre of themaze, the head in the
direction of a closed arm. Over a 5 min period, they were
evaluated for the time spent in the open and closed arms
(55 cm from the ﬂoor, 12 cmr50 cm arms; Monteggia
et al., 2007).
Rotarod
The rotarod test was performed to evaluate motor co-
ordination. Animals were placed on immobile cylinders,
which ramped up from 0 to 45 rotations/min (IITC,
USA). The timer was stopped when the mouse fell oﬀ the
cylinder or did a whole turn with it. This procedure was
repeated three consecutive times.
Nociceptive tests
Mechanical noxious threshold was determined using
the von Frey microﬁlaments (Bioseb, France) as described
previously (Yalcin et al., 2011). Mice were placed in
Plexiglas boxes (7 cmr9 cmr7 cm) on an elevated grid.
Calibrated ﬁlaments were applied on the plantar surface
of the hindpaw. The ﬁlaments were tested ﬁve times
per paw in ascending forces until the paw withdrawal
threshold was reached (Barrot, 2012). Noxious threshold
was deﬁned as the lower ﬁlament for which three or more
withdrawals were observed. The cut-oﬀ was set at 15 g.
Thermal noxious response was determined using a hot
plate (IITC). Mice were placed on a 52 xC plate, in a
Plexiglas cylinder and latency to ﬁrst paw licking was
used to deﬁne noxious thermal threshold. The cut-oﬀ
time was set at 50 s.
To evaluate opiate-induced analgesia, morphine
(10 mg/kg) and saline were injected s.c. 30 min prior to
testing. Mechanical and thermal responses were assessed
in independent sets of mice.
Intra-CeA TrkB-Fc injection
Mice implanted with guide cannulas were tested for
morphine-induced mechanical analgesia after CeA bilat-
eral infusion of the BDNF scavenger TrkB-Fc. TrkB-Fc
(0.5 ml per side ; R&D Systems; 0.1 mg/ml in PBS) or PBS
was delivered via a 33-gauge cannula that extended
500 mm below the end of the guide cannula. Injections
were performed at a constant rate over 2.5 min (CMA 400
Syringe Pump). The cannula was left in place for 5 min
before removing it. One hour later, mice received mor-
phine (10 mg/kg s.c.). Mechanical noxious thresholds
were determined 20 min before morphine injection
(40 min after intra-CeA TrkB-Fc or PBS infusion) and
20 min after morphine injection (80 min after TrkB-Fc or
PBS infusion).
Morphine-induced c-Fos response
Five wk following AAV injection in the PB, animals re-
ceived a saline injection the day prior to the experiment
for habituation to the procedure. The day of the exper-
iment, 2 h after morphine (10 mg/kg s.c.) or saline
injection, animals were anaesthetized and ﬁxed using
standard procedures (Sarhan et al., 2005). Brains were
sectioned on a vibratome (40 mm frontal sections) and
immunostained for c-Fos. Free-ﬂoating sections were
washed in PBS and endogenous peroxidase activity was
blocked (50% ethanol, 1% H2O2). After PBS washes, as-
peciﬁc binding sites were saturated in 5% donkey serum
in PBS 0.3% triton (PBS-t) and incubation in primary
antibody (rabbit anti-c-Fos 1 :2000, Santa Cruz
Biotechnology, SC-52 ; 1% donkey serum; PBS-t 0.3%)
was done overnight (Kauﬂing et al., 2009). Next, sections
were washed, incubated with secondary biotinylated
antibody (donkey anti-rabbit, 1 :200, GE Healthcare,
UK; 1% donkey serum), washed and incubated in
ABC kit (1 :500; ABC Elite, Vector Laboratories, USA).
Diaminobenzidine revelation was performed (DAB
0.0125%, H2O2 0.0009%) and after extensive washes, sec-
tions were mounted on gelatine-coated slides, air-dried
and coverslipped with Eukitt (O. Kindler GmbH,
Germany). c-Fos positive nuclei were counted in the BLA,
the dorsal BSTL and the capsular (CeC), lateral (CeL) and
medial (CeM) subdivisions of the CeA using a micro-
scope attached to a camera Lucida. On average, four
sections per animal were counted for the BSTL and 4–6
for the BLA and the CeA.
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Histology
At the end of the behavioural experiments, anaesthetized
animals were ﬁxed and the brains were sectioned on a
vibratome (40 mm frontal sections). For BDNF PB deletion
experiments, the PB was examined under ﬂuorescence
for eGFP expression. For intra-CeA TrkB-Fc experiments,
the bilateral placement of cannulas was assessed on
Cresyl Violet stained sections. Pictures were taken using
an epiﬂuorescence microscope (Leica) with a digital
camera (Cool Snap, USA) or using a Nikon E80i micro-
scope. Adobe Photoshop (Adobe, USA) was used to ad-
just contrast, brightness and sharpness.
Statistical analysis
Data are expressed as mean¡S.E.M. and analyses were
performed with STATISTICA 8 (Statsoft, USA). To assess
eﬀects on morphine-induced analgesia, multifactor
analysis of variance was used. When appropriate, the
Neuman–Keuls test was used for post hoc comparisons.
For analysis of c-Fos induction, Student’s t test was used
for two groups’ comparisons. The signiﬁcance level was
set at p<0.05.
Results
Anatomical substrate for the parabrachial BDNF
projection
Tract tracing
Anterograde tracer injections (n=2 for successful place-
ment of injection site) targeting the PB (lateral PB, exter-
nal part, PBel ; Fig. 1i) led to terminal ﬁbre labelling in
the CeL, the CeC and the dorsal BSTL (Fig. 1ii, iii), with
very few labelled regions outside of them. Moreover,
retrograde tracing from the CeA (n=2 for successful
placements) resulted in strong labelling of cell bodies
concentrated into the PBel (Fig. 1iv, v). These results es-
tablish that our subsequent AAV injections targeted the
PB-EAc pathway.
Local BDNF deletion
The placement and extent of the AAV injections were
assessed by the presence of eGFP-positive neurons for
both control (eGFP alone) and BDNF-deleted animals
(eGFP-Cre fusion). eGFP labelling had to be present and
concentrated in the lateral PB for the injection placement
to be considered as valid, although it often also included
labelling spreading into the median PB. The pontine
PB was the main targeted area, but some injections dis-
played a larger rostro-caudal spread, thereby also in-
cluding the mesencephalic PB (Fig. 2a, b, d). eGFP
expressing neurons were often clustered in the external
aspect of PB, namely, the external lateral, lateral crescent
and external medial nuclei. Animals were included for
data analysis if the viral infection comprised the lateral
PB, remained within the boundaries of the PB and was
validated bilaterally.
Cellular aspects of the eGFP labelling diﬀer whether or
not it is fused to the Cre recombinase. eGFP alone, in
control animals, is cytoplasmic and displays a labelling
that ﬁlls the entire soma as well as its dendritic (Fig. 2c)
and axonal processes. Terminal axonal labelling can be
observed in brain regions receiving aﬀerents from the
injection site. Strong eGFP labelling was found in both
the lateral part of the CeA (CeL and CeC) and the dorsal
BSTL for all control animals (Fig. 2 f–h). Moreover, the
eGFP-positive terminals in these structures display the
characteristic pericellular basket appearance (Fig. 2h)
described for CGRP-containing terminals in the CeA and
BSTL. When fused to the Cre recombinase, the eGFP
labelling appears nuclear (Fig. 2e), while the number of
infected cells per injection site was comparable in both
control and deleted animals.
In agreement with previous reports (Berton et al.,
2006 ; Monteggia et al., 2007; Adachi et al., 2008 ; Koo
et al., 2012) in diﬀerent brain regions, in situ hybridi-
zation reveals a decrease in BDNF mRNA levels in
BDNF-deleted animals (Fig. 2 i, j). In all animals, BDNF
appears concentrated in few brain nuclei, but BDNF
transcripts were highly expressed in the PBel in con-
trol animals, as opposed to AAV-eGFP-Cre injected
animals.
Parabrachial BDNF mediates morphine-induced
analgesia
General behavioural assessment
Following histological validation, 10 control and 10
BDNF-deleted animals were used for behavioural analy-
ses. Prior to morphine-induced analgesia measurement,
animals were assessed for their anxiety levels and motor
skills. No diﬀerences were noted for anxiety levels as
measured by the dark–light, elevated plus-maze and
open-ﬁeld tests (Fig. 3a–d). Similarly, motor coordination
measured using the rotarod was not altered by BDNF
deletion in the PB (Fig. 3g). Finally, no diﬀerence was
observed for general locomotor activity in the open-ﬁeld
test (Fig. 3 f).
Morphine-induced analgesia
In the hot-plate test, control and BDNF-deleted animals
displayed similar responses following saline injections
(Fig. 4a). Morphine-induced analgesia was present in
both groups, but it dramatically decreased in PB BDNF-
deleted animals (38% reduction, p<0.001). Both controls
and BDNF-deleted animals showed a tolerance to the
analgesic properties ofmorphine (Fig. 4a), with the largest
drop in eﬃcacy noted for the second day of morphine
injection. Following tolerance procedure, thermal no-
ciceptive response was reassessed, with both groups
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again showing similar values in response to saline injec-
tions (Fig. 4a).
Mechanical nociceptive response was evaluated in an
independent experiment. Similar to thermal sensitivity,
no baseline diﬀerence was noted between control and
BNDF-deleted animals (Fig. 4b), but morphine-induced
analgesia was reduced in BDNF-deleted animals (58%
reduction, p<0.001; Fig. 4b).
(a)
(ii)
(i)
BSTL
CeA
PB
BLA
BLA
200 µm
(iii)
(iv)
(v)
Fig. 1. Parabrachio-amygdaloid pathway in mouse. (a) Shows the structures of interest (boxed areas) on frontal brain sections drawings
(adapted from Franklin and Paxinos, 2008). After deposit of biotin dextran amine in the parabrachial nucleus (PB; i, black arrow),
anterogradely labelled axons are found in the lateral part of the central nucleus of the amygdala (CeA; ii) and in the dorsal part of the
lateral bed nucleus of stria terminalis (BSTL; iii). Retrogradely labelled somas are found in the PB (iv) after Fluoro-gold1 injection in
the CeA (v, white arrow). Scale bars : 200 mm. ac, anterior commissure ; dorsal (D), ventral (V), posterior (P) parts ; BLA, basolateral
amygdala ; lateral (CeL), capsular (CeC), medial (CeM) parts ; CPu, caudate putamen; ic, internal capsule ; ot, optical tract ; lateral (l),
lateral external (el), medial (m) parts ; scp, superior cerebellar peduncle.
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BDNF into the CeA mediates morphine-induced
analgesia
Following histological validation of cannula placement,
morphine-induced mechanical analgesia was analysed
on nine mice with intra-CeA PBS (control mice) and six
mice with intra-CeA TrkB-Fc (TrkB-Fc mice). The no-
ciceptive thresholds before morphine injection were
similar between control and TrkB-Fc mice (Fig. 4c), but a
decrease in morphine-induced analgesia was observed in
TrkB-Fc mice (49% reduction, p<0.001 ; Fig. 4c).
Parabrachial BDNF mediates morphine-induced early
cellular responses
In both control and BDNF-deleted animals, morphine
injection increased the number of c-Fos positive nuclei in
the dorsal BSTL, the BLA and the three subdivisions of
µm
µm
µm
µm
(a)
(b) (c)
(e) (J)(d)
(i)
(f ) (g) (h)
µm
µm
µm
µm µm µm
Fig. 2. Adeno-associated virus (AAV) injections. Enhanced green ﬂuorescent protein (eGFP) expression in the parabrachial nucleus
(PB) following AAV-eGFP (a–c) or AAV-eGFP-Cre (d, e) injections. Following AAV-eGFP injection in the external lateral PB (PBel),
ﬂuorescent terminals are observed in the central nucleus of the amygdala (CeA; f) and in the lateral bed nucleus of stria terminalis
(BSTL; g, h) with typical perisomatic basket appearance. In situ hybridization, with optical density changes converted to a colour
scale shows a decrease in brain-derived neurotrophic factor (BDNF) mRNA levels in the external lateral PB (white arrowheads) of
AAV-eGFP-Cre injected mice (j) as compared to AAV-eGFP controls (i). Lateral (l), medial (m) parts ; scp, superior cerebellar peduncle.
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Fig. 3. Behavioural measure (¡S.E.M) of anxiety using the dark–light (a, b), the elevated plus-maze (c, d) and the open-ﬁeld (e, f) tests.
Locomotor activity was assessed with the open-ﬁeld (f) and motor coordination with the rotarod test (g). eGFP, enhanced green
ﬂuorescent protein.
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the CeA (Fig. 5e). In control animals, the number of c-Fos
positive nuclei was at least doubled (BSTL 171%, CeC
176% and CeM 233% over saline), with the largest
morphine-induced elevations being counted in the CeL
(929%) and the BLA (187%; Fig. 5e). No diﬀerence be-
tween control and BDNF-deleted animals is noted for
responses to saline, but these groups diﬀer widely when
comparing their response to morphine (Fig. 5a–d). More
speciﬁcally, c-Fos positive nuclei were reduced by ap-
proximately 50% in both the dorsal BSTL (control vs.
BDNF-deleted groups, p<0.05) and the CeL (p<0.05),
while the CeC, CeM and BLA were equally responsive to
morphine regardless of the PB deletion (Fig. 5e).
Discussion
We used tract-tracing techniques to visualize the mouse
parabrachio-amygdaloid projection, a pharmacological
approach to block BDNF actions in the CeA and molecu-
lar tools to delete the BDNF gene in the PB. From a cellular
perspective, this deletion led to a decrease in c-Fos in-
duction in the CeL and BSTL following morphine ad-
ministration. From a behavioural perspective, it resulted
in decreased morphine-induced analgesia. This reveals
an essential role for the BDNF parabrachio-amygdaloid
pathway in opiate-induced analgesia.
Morphological and functional aspects of the spino-
parabrachio-amygdaloid nociceptive pathway have been
thoroughly described in rats (Bernard et al., 1996; Sarhan
et al., 2005). While it is expected to be similar in mice,
supporting evidence is only starting to emerge (Tokita
et al., 2010). Here, both anterograde and retrograde trac-
ing methods showed that neurons in PBel extensively
project to the EAc in mice. In addition, the anterograde
transport of eGFP expressed by AAV-infected neurons
in the PBel led to terminal labelling in the EAc, thus
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Fig. 4. Eﬀect of brain-derived neurotrophic factor parabrachial nucleus deletion (a, b) and TrkB-Fc infusion into central nucleus of the
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conﬁrming the targeting of the PB-EAc pathway. It
should also be noted that, in the rat, PB neurons project-
ing to the EAc, notably those in the PBel, do not innervate
other structures except a light projection to the lateral
hypothalamus and midbrain reticular formation (Sarhan
et al., 2005).
BDNF immunoreactivity was described in the CeA
and BSTL in rats and mice (Conner et al., 1997 ; Yan et al.,
1997 ; Krause et al., 2008). In the PB, a BDNF immuno-
reactive plexus is described along with BDNF expressing
neurons (Ceccatelli et al., 1991 ; Conner et al., 1997) and
these neurons project to the ipsilateral EAc (Conner et al.,
1997). Distinctive pericellular structures are described for
the EAc BDNF terminal labelling, featuring a similar
morphology to the axonal terminals originating from the
PB-EAc projection (Conner et al., 1997; Sarhan et al.,
2005 ; Agassandian et al., 2006). Locally, dense core
vesicles were shown to contain simultaneously BDNF,
substance P and CGRP (Salio et al., 2007). Furthermore,
the BDNF receptor TrkB was post-synaptically described
in the EAc (Yan et al., 1997 ; Agassandian et al., 2006).
Behaviourally, both EAc (Davis et al., 2010) and BDNF
(Rattiner et al., 2004; Monteggia et al., 2007) were im-
plicated in anxiety-like behaviours. Indeed, BDNF global
deletion leads to enhanced anxiety-related behaviour
(Rios et al., 2001). However, our results suggest that the
parabrachio-amygdaloid pathway may not be relevant
in this context since local manipulation of BDNF in the
PB is not accompanied by a change in anxiety.
The spino-parabrachio-amygdaloid pathway carries
nociceptive information to the EAc, which then mediates
sensorimotor, emotional and aﬀective dimensions of pain
(Neugebauer et al., 2009). This is achieved via connec-
tions with ascending and descending nociceptive systems
(Oliveira and Prado, 2001 ; Neugebauer et al., 2009).
Lesion studies demonstrated that the CeA is not critical
for generating the physical response to acute pain, but it is
involved in the expression of several forms of analgesia,
such as conditioned- or stress-induced (Helmstetter, 1993 ;
Helmstetter et al., 1993 ; Watkins et al., 1993 ; Manning
and Mayer, 1995). The CeA inactivation or lesion also
reduces morphine-induced analgesia (Manning and
Mayer, 1995 ; Manning et al., 2001) and, while systemic
morphine is expected to exert its properties on multiple
relays along the pain matrix, this indicates that CeA is a
required element of the anti-nociceptive circuit recruited
by morphine. Moreover, morphine and b-endorphin
injections into the amygdala were shown to induce anal-
gesia through periaqueductal grey (PAG) connections
(Helmstetter et al., 1993 ; Pavlovic and Bodnar, 1998), thus
suggesting that morphine can directly act on CeA cir-
cuitry. The three opioid receptors subtypes are present in
the EAc, both pre and post-synaptically (Zhu and Pan,
2005 ; Jaferi and Pickel, 2009 ; Poulin et al., 2009). In the
three CeA subdivisions, neurons can be post-synaptically
inhibited by m-receptor agonists (Chieng et al., 2006), but
presynaptic inhibition of glutamate or GABA release
has also been reported (Finnegan et al., 2005 ; Zhu and
Pan, 2005). We found that acute morphine injection in-
creased the number of neurons expressing c-Fos in the
CeA, dorsal BSTL and BLA, which is consistent with
previous reports (Hamlin et al., 2007). As almost all EAc
neurons are GABAergic (Alheid et al., 1995 ; Cassell et al.,
1999), and activation of m-receptors usually results in an
inhibitory outcome, the local eﬀects of morphine would
mainly be due to disinhibitory mechanisms. Thus, mor-
phine would mimic the physiological activation of the
opioid system in the CeA to promote anti-nociceptive
processes normally activated during life-threatening
situations. The cellular mechanisms underlying this acti-
vation are, however, poorly understood.
Part of the inhibitory circuit of the mice CeA has been
recently disclosed in the context of fear conditioning
(Ciocchi et al., 2010; Haubensak et al., 2010). It has been
suggested that, in the CeL, GABA neurons (OFF cells)
tonically inhibit CeM projection neurons responsible for
fear-induced freezing. Another population of GABA CeL
neurons (ON cells) can be excited by BLA and/or cortical
aﬀerents following presentation of a shock-paired tone.
As a consequence, ON cells would inhibit OFF cells, thus
disinhibiting CeM neurons and triggering the activation
of defensive pathways in the brainstem. As hypoalgesia
occurs during expression of conditioned fear, it could
be suggested that a similar circuit in the CeA controls
conditioned analgesia. However, while Finnegan et al.
(2005) proposed that m-receptor agonists trigger the dis-
inhibition of CeM PAG-projecting neurons, Chieng
and Christie (2009) suggest the contrary, i.e. inhibition
of CeM projection neurons. Several neuropeptides
such as oxytocin, neurotensin, corticotrophin-releasing
factor and CGRP also induce opioid-dependent anti-
nociception when injected into the CeA (Kalivas et al.,
1982 ; Xu et al., 2003 ; Cui et al., 2004 ; Han and Yu, 2009).
This would be achieved, at least for oxytocin, through the
inhibition of CeM projection neurons since oxytocin acti-
vates ON cells in the lateral CeA and decreases freezing
(Haubensak et al., 2010 ; Knobloch et al., 2012). Finally,
in addition to its anti-nociceptive roles, the CeA is
also involved in pro-nociceptive processes, especially
during prolonged pain (Neugebauer et al., 2009). A bi-
directional control of CeA output has thus to be achieved
either through a single circuit with both anti- and
pro-nociceptive potentialities or through the balance
between two opposite circuits. Our results show that
deleting BDNF from the PB-EAc pathway, or directly
inhibiting BDNF actions in the CeA, reduces morphine-
induced analgesia. It is thus possible that BDNF is
involved in maintaining the balance in CeA circuits
and in tuning the reactivity to emotionally relevant
situations.
BDNF has been thoroughly studied in the context of
pain modulation, but most studies focused on the spinal
level (Pezet et al., 2002 ; Ren and Dubner, 2007 ; Merighi
et al., 2008). BDNF involvement in supraspinal pain
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mechanisms was explored in the PAG and its main
downstream eﬀector, the rostroventromedial medulla
(RVM). Midbrain BDNF infusions (Guo et al., 2006) as
well as intracerebroventricular administrations (Cirulli
et al., 2000) appear anti-nociceptive without aﬀecting
basal nociceptive thresholds. In contrast, BDNF trans-
mission within the RVM appears pro-nociceptive and
facilitates hyperalgesia (Guo et al., 2006). Thus the BDNF
pathways are part of descending pain control systems
with both anti-nociceptive and pro-nociceptive roles.
Interestingly, TrkB controls morphine-induced analgesia
without aﬀecting basal nociceptive responses (Lucas et
al., 2003). Our results are consistent with these data, since
suppressing BDNF in the PB-EAc projection results in
unaltered basal pain responses, but decreases morphine-
induced analgesia. From a cellular aspect, morphine
increases c-Fos expression in all analysed EAc nuclei as
well as in the BLA. In BDNF-deleted mice, this induction
is reduced in the CeL and dorsal BSTL, but not in the
BLA. Since the CeL and the dorsal BSTL are directly
innervated by PB axons containing BDNF (Conner et al.,
1997), it appears that cellular recruitment in the EAc in
response to morphine is, at least partially, dependent on
BDNF released by PB terminals.
Our results suggest that BDNF is necessary to obtain
eﬀective morphine-induced analgesia. Several mechan-
isms can be proposed. BDNF may act in the PB itself by
modifying dendritic morphology (Horch, 2004) or by
modulating the expression of neuropeptides such as CGRP
in parabrachio-amygdaloid neurons. If BDNF regulates
PB expression and/or release of CGRP, it would eventu-
ally impact its main anatomical target, the EAc. However,
the role of CGRP in pain-related mechanisms in the CeA
remains controversial, both pro-nociceptive (Han et al.,
2010) and anti-nociceptive (Xu et al., 2003) actions being
reported. While we cannot rule out a local action of BDNF
in the PB, the behavioural eﬀect of TrkB-Fc infusion in the
CeA shows that BDNF can modulate morphine analgesia
by an acute local eﬀect in the CeA. BDNF-TrkB signalling
is able to facilitate glutamatergic transmission (Guo et al.,
2006 ; Ren and Dubner, 2007 ; Merighi et al., 2008) and
also leads to the rapid internalization of GABAA receptors
in the amygdala, allowing for transient hyperexcitability
(Mou et al., 2011). In the CeA, BDNF is present in peri-
cellular pre-synaptic terminals containing glutamate
(Agassandian et al., 2006 ; Delaney et al., 2007). Post-
synaptically, both BDNF and TrkB immunoreactivities
are detected on post-synaptic densities of asymmetric
synapses facing BDNF-positive axons, presumably from
PB origin, but also BDNF-negative axons from BLA
or cortical origin (Agassandian et al., 2006). PB-derived
BDNF in the CeA may thus modulate excitatory sy-
napses. In a given physiological situation, this would
allow selecting a speciﬁc circuit by targeted disinhibition
via the opioid system and enhanced excitation via the
BDNF system. During morphine analgesia, m-receptors in
the CeL could thus trigger the silencing of a GABA
population, thus disinhibiting a second population
that could be activated by BDNF-potentiated excitatory
aﬀerents. The absence or blockade of BDNF in our ex-
periments would reduce this excitation, as suggested
by the decreased c-Fos recruitment in the CeL, and
consequently reduce the positive inﬂuence of CeA on
anti-nociceptive processes. Interestingly, the CeC has
often been associated with pro-nociception while the CeL
has been more associated with anti-nociception (Hamlin
et al., 2007 ; Neugebauer et al., 2009). It is, however, too
speculative to further develop a potential circuit for
BDNF action in the CeA. First, we do not know if PB
inputs preferentially target ON or OFF cells or another
group. The PB in the rat indeed projects to CeL and CeC
via diﬀerent neuronal populations (Sarhan et al., 2005)
and the distribution of ON and OFF cells in the CeA has
not been described with enough precision to diﬀerentiate
between CeL and CeC. Second, the correlation between
the CeA distribution of m-receptors and their cellular
and behavioural eﬀects is only partial and controversial.
Third, whereas morphine can directly act on m-receptors
in the CeA, the overall changes in CeA activity, including
those involving BDNF, can also be due to m-receptors
in CeA-projecting structures, such as the intercalated
cell masses, which provide an inhibitory input to the
CeA (Palomares-Castillo et al., 2012). Dissecting the
mechanisms of BDNF action in the CeA will thus need
additional anatomical and functional studies.
The potential role of BDNF in the BSTL remains elu-
sive. We show that BDNF deletion in the PB-EAc pathway
leads to decreased morphine-induced c-Fos activation in
the dorsal BSTL, similar to what was observed in the CeL.
The CeA and the BSTL share similar cytoarchitectural,
neurochemical and hodological features and are strongly
interconnected (Alheid et al., 1995 ; Cassell et al., 1999).
BDNF innervation in the BSTL originates in the PB
(Conner et al., 1997) and PB-BSTL axons arise as col-
laterals of PB neurons innervating the CeA (Sarhan et al.,
2005). However, our TrkB-Fc experiment shows that
blocking BDNF signalling in CeA is suﬃcient to decrease
morphine-induced analgesia. Indeed, while the role of
BSTL in pain is less studied than the CeA, it may be
mainly related to aﬀective and neuroendocrine dimen-
sions (Deyama et al., 2007), with little or no evidence of
an involvement in nociceptive sensitivity. Thus, BDNF in
the BSTL may be involved in a circuit similar to the CeA,
but with a preferential impact on the aﬀective aspects of
pain.
This study shows that BDNF produced in the PB-EAc
pathway is important for morphine analgesia. BDNF
deletion in PB neurons leads to a signiﬁcant decrease in
c-Fos response to morphine in the CeL and BSTL. This
deletion does not alter baseline nociceptive responses,
but aﬀects the analgesic properties of morphine.
While further research is necessary to address the
implications of supraspinal BDNF in nociception pro-
cesses, this study provides candidate anatomical and
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molecular substrates that are likely involved in opiate
analgesia.
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